• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
HGEN

HGEN

Humanigen, Inc.

NASDAQHealthcareBiotechnologyUS

USD0.00

-0.00 (-84.62%)

Company Profile

CEO

Cameron Durrant MBA

IPO Date

2013-01-31

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$0.00

Prev. Close

$0.00

Day Low

$0.00

Day High

$0.00

52W Low

$0.00

52W High

$0.24

Volume

2.06M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

64.7%

Avg Negative

1.4%

Avg Neutral

34.0%

News Feed

NIH Advances ACTIV-5/BET-B Trial Evaluating Lenzilumab from a Phase 2 Exploratory Study to a Phase 2/3 Study for the Treatment of COVID-19

Business Wire·7/30/2021·↑ positive

Humanigen's Partner in South Korea Receives Ministry of Food and Drug Safety (MFDS) Approval to Conduct Phase 1 Study of Lenzilumab

Business Wire·7/22/2021·↑ positive

Humanigen Stock Increases Over 5%: Why It Happened

Pulse2·7/9/2021·↑ positive

UK's MHRA accepts Humanigen's submission of Lenzilumab for Marketing Authorization in COVID-19 for expedited rolling review

Business Wire·7/9/2021·↑ positive

Humanigen Inc. Added to Russell 3000(R) Index

Newsfile Corp·6/28/2021·↑ positive

Humanigen Initiates Submission for Lenzilumab Marketing Authorization in COVID-19, to the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA)

Business Wire·6/14/2021·↑ positive

Humanigen Files US Emergency Use Application For Lenzilumab For COVID-19

Benzinga·5/28/2021·↑ positive

Humanigen to Present at Jefferies Healthcare Conference

Business Wire·5/19/2021·↑ positive

Humanigen Recruits Chime Biologics As Manufacturing Partner For Lenzilumab

Benzinga·5/17/2021·↑ positive

Humanigen Shares Gain On FDA Emergency Filing Plans For COVID-19 Drug By June

Benzinga·5/14/2021·↑ positive